Tibilive 2,5 mg Tablet
PDF Leaflet Revision Date: 14 May 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Symptomatic treatment of menopause-related hot flushes and prevention of post-menopausal osteoporosis.
Dosage (summary)
1 tablet daily; start at least 12 months after last natural bleed.
Onset of Action / Duration
Onset: weeks, Duration: optimal results after 3 months.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Anticoagulants
- CYP3A4 inducers
- St. John's wort
Contraindications
- Hypersensitivity to tibolone
- Hormone-dependent tumors
- History of venous thromboembolism
- Active liver disease
- Endometrial hyperplasia
Common side effects
- Dizziness
- Headache
- Vaginal discharge
- Breast tenderness
- Weight increase
Counselling Points
- Report any unusual bleeding
- Regular breast examinations
- Avoid in pregnancy and breastfeeding
Serious warnings
- Increased risk of stroke
- Increased risk of breast and endometrial cancer
- Thromboembolic events
Important Disclaimer
The Tibilive 2,5 mg Tablet professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
